Cargando…
Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy
Personalized medicine in treating pancreatic ductal adenocarcinoma (PDAC) is still in its infancy, albeit PDAC-related deaths are projected to rise over the next decade. Only recently, maintenance therapy with the PARP inhibitor olaparib showed improved progression-free survival in germline BRCA1/2-...
Autores principales: | Roger, Elodie, Gout, Johann, Arnold, Frank, Beutel, Alica K., Müller, Martin, Abaei, Alireza, Barth, Thomas F. E., Rasche, Volker, Seufferlein, Thomas, Perkhofer, Lukas, Kleger, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563330/ https://www.ncbi.nlm.nih.gov/pubmed/32948057 http://dx.doi.org/10.3390/cells9092110 |
Ejemplares similares
-
A Prospective Feasibility Trial to Challenge Patient–Derived Pancreatic Cancer Organoids in Predicting Treatment Response
por: Beutel, Alica K., et al.
Publicado: (2021) -
DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives
por: Perkhofer, Lukas, et al.
Publicado: (2021) -
Pancreatic Ductal Organoids React Kras Dependent to the Removal of Tumor Suppressive Roadblocks
por: Perkhofer, Lukas, et al.
Publicado: (2019) -
Serum IgG4 levels outperform IgG4/IgG RNA ratio in differential diagnosis of IgG4-related disease
por: Schulte, Lucas A., et al.
Publicado: (2020) -
Precision medicine meets the DNA damage response in pancreatic cancer
por: Perkhofer, Lukas, et al.
Publicado: (2018)